Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigiis 101-LAB in H. pylori Eradication
NCT03722433Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2018
- Primary completion
- Jul 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lactobacillus paracasei NTU 101 in Helicobacter pylori infection (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Incidence of adverse effects in the first line therapy at 8 weeks. Status: unknown.
02
Drugs
lactobacillus paracasei NTU 101
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03722433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722433.